Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 226

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 226
---
X)) a Nasdaq-based novel small molecule anti-viral and oncology therapeutics
company with products in various clinical trials. Mr. Stover has also been a member of the board of directors of Stero Therapeutics,
Inc., a private medical company, since February 2024. Mr. Stover was appointed to the board of directors and chairman of the
audit committee of PharmaCyte Biotech, Inc. (PMBC) effective August 15, 2022 and resigned from the Board effective November 1,
2022. From June 2016 to November 2020, Mr. Stover served as president, chief executive officer and director of Interpace
Biosciences, Inc., (IDXG) a publicly-traded small cap life sciences company providing complex molecular analysis for the early diagnosis
and treatment of cancer and supporting the development of targeted therapeutics and previously from December 2015 until June 2016,
served as interim president and chief executive officer of IDXG. Mr. Stover was also on the board of directors of IDXG from
August 2005 until November 2020, and was chairman of the audit committee from August 2005 until December 2015. From
June 2016 to December 2016, Mr. Stover was chairman of the audit committee and a member of the board of directors of Viatar
CTC Solutions, Inc. From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly
held specialty pharmaceutical company then listed on the American Stock Exchange. In addition to other relevant experience, Mr. Stover
was also formerly a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience industry division in Pennsylvania
and New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant. We believe
that Mr. Stover is well-qualified to serve as a director of our company based on Mr. Stover’s experience holding
senior leadership positions in the life sciences industry, and his specific experience and skills in the areas of general operations,
financial operations and administration.

No director is related to any
other director or executive officer of our company or our subsidiaries, and, there are no arrangements or understandings between a director
and any other person pursuant to which such person was elected as director.

<div align='center'>132